The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention relates to a compound of formula (I) in which L.sup.1, A, X.sup.1, X.sup.2, X.sup.3, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.9, R.sup.10, m, and n are as defined in the description, or a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a tautomer thereof, and a use thereof as an RET, SRC and/or BTK kinase inhibitor in the treatment of diseases such as cancers.

##STR00001##

The present invention relates to a compound of formula (I) in which L.sup.1, A, X.sup.1, X.sup.2, X.sup.3, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.9, R.sup.10, m, and n are as defined in the description, or a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a tautomer thereof, and a use thereof as an RET, SRC and/or BTK kinase inhibitor in the treatment of diseases such as cancers.

##STR00001##

The disclosure provides compounds of Formula (I) ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein W.sup.1, W.sup.2, Y, Z, M, L, C.sup.y, C.sup.z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.2a, R.sup.y, R.sup.z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

The disclosure provides compounds of Formula (I) ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein W.sup.1, W.sup.2, Y, Z, M, L, C.sup.y, C.sup.z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.2a, R.sup.y, R.sup.z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Disclosed are a kind of fused ring derivatives, and specifically disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.

##STR00001##

The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.

The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.

Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): ##STR00001##
pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.

Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): ##STR00001##
pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.